Eylea wins new approval in Japan; EC to decide on Perrigo buyout by July 29;

@FiercePharma: Egg prices soar, menu items dropped in wake of historic avian flu. FierceAnimalHealth article | Follow @FiercePharma

@EricPFierce: France's TxCell closes its plant at ANSM urging to avoid contamination. FiercePharmaManufacturing article | Follow @EricPFierce

> Kamil Hamied, who was widely expected to succeed his uncle to lead Indian drugmaker Cipla, has left the company to pursue his own interests. Story

> The European Commission has said it will decide by July 29 whether to allow Mylan ($MYL) to continue its effort to buy Ireland-based Perrigo ($PRGO). Report

> Regeneron ($REGN) says that Bayer, its partner on hot-selling eye drug Eylea, has gained approved of the med in Japan for treating macular edema secondary to branch retinal vein occlusion (BRVO). Release

> Roche ($RHHBY) has opposed French drugmakers who are suggesting the use of its Avastin for off-label use as a cheaper way to treat wet age-related macular degeneration (AMD). Report

Medical Device News

@FierceMedDev: Cinven snatches up Synlab for $1.96B to beef up in diagnostics. FierceDiagnostics news | Follow @FierceMedDev

@VarunSaxena2: Valeant makes offer for Zoetis, sources tell WSJ. FiercePharma story | Follow @VarunSaxena2

@EmilyWFierce: $ILMN just signed a 20-year lease for a new 155,000 square foot scientific research building in England. Release | Follow @EmilyWFierce

> BlackBerry unveils plans for bacteria-free smartphone device. More

> European researchers develop thought-controlled robot. Article

Biotech News

@FierceBiotech: Harvard team makes 'sweating' vehicles for liquid drug delivery. FierceDrugDelivery story | Follow @FierceBiotech

@JohnCFierce: Big story yesterday: Bristol-Myers rips up its R&D group, adding, eliminating and moving 800-plus Hubs win. Report | Follow @JohnCFierce

@DamianFierce: From BIO last week, here's $QURE CEO Aldag talking about $CLDN, $AAVL and the future of gene therapy. Listen | Follow @DamianFierce

> Billionaire Soon-Shiong arranges a $71M crossover round for Conkwest. News

> Seres guts out a $134M IPO to fuel microbiome R&D. Article

> Celladon pulls the plug on R&D after a crushing gene therapy failure. Report

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.